Trial NCT00039091

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2012-03144
Secondary IDs: 01-228 CDR0000069349 R21CA105776

Last trial update was posted on 2018-09-05

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Immunoglobulins Ipilimumab

MeSH Conditions

Carcinoma, Non-Small-Cell Lung Carcinoma, Ovarian Epithelial Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Lung Neoplasms Melanoma Myelodysplastic Syndromes Myelodysplastic-Myeloproliferative Diseases Myeloproliferative Disorders Preleukemia Recurrence Syndrome

Other Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Myeloid Leukemia Recurrent Melanoma Recurrent Non-small Cell Lung Cancer Recurrent Ovarian Epithelial Cancer Stage IV Melanoma Stage IV Non-small Cell Lung Cancer

Stopping Reasons

N/A

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID